Natalizumab-related PML 2 weeks after negative anti-JCV antibody assay
- 2 February 2016
- journal article
- case report
- Published by Wolters Kluwer Health in Neurology
- Vol. 86 (5) , 484-486
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Maraviroc and JC Virus–Associated Immune Reconstitution Inflammatory SyndromeNew England Journal of Medicine, 2014
- JC Viremia in Natalizumab-Treated Patients with Multiple SclerosisNew England Journal of Medicine, 2013
- Risk of Natalizumab-Associated Progressive Multifocal LeukoencephalopathyNew England Journal of Medicine, 2012
- Anti‐John Cunnigham virus antibody prevalence in multiple sclerosis patients: Baseline results of STRATIFY‐1Annals of Neurology, 2011
- Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 casesThe Lancet Neurology, 2010